PMID- 16723631
OWN - NLM
STAT- MEDLINE
DCOM- 20061220
LR  - 20220321
IS  - 1522-8517 (Print)
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Linking)
VI  - 8
IP  - 3
DP  - 2006 Jul
TI  - An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating 
      lymphocytes of human glioblastoma multiforme.
PG  - 234-43
AB  - The subpopulation of CD4+CD25+ immunoregulatory T (Tr) cells constitutes 5%-10% 
      of CD4+ cells in humans. These cells play a crucial role in the control of tumor 
      immune response. In this study, we evaluated the distribution of Tr cells in 
      tumor-infiltrating lymphocytes of human glioblastoma multiforme and examined the 
      difference between the brain and autologous blood with respect to Tr cells. 
      Glioma samples from 10 patients were classified as WHO grade IV astrocytoma. 
      Control samples were obtained from patients undergoing resection of a seizure 
      focus. The samples were analyzed by flow cytometry to determine the frequency of 
      Tr cells and by real-time PCR for forkhead box P3 (FOXP3) expression. We then 
      examined the expression of CD62L, CD45RO, and cytotoxic T-lymphocyte-associated 
      protein 4 (CTLA-4) and assessed the functionality of Tr cells in vitro. There was 
      a significant difference in the number of FOXP3-expressing CD4+CD25+ T cells 
      within glioma-infiltrating lymphocytes as compared to controls (P < 0.01). This 
      difference was further observed in studies of autologous patient blood and 
      control blood. The expression level of FOXP3 mRNA was high in Tr cells and weak 
      in CD4+CD25-T cells. Moreover, the expression of CD62L and CTLA-4 was elevated in 
      glioma Tr cells as compared to that in the controls. These cells were also CD45RO 
      positive. Functional assays confirmed the suppressive activity of Tr cells in 
      patients with glioma. The expression of CD4+CD25+FOXP3+ T cells was significantly 
      higher in patients with glioblastoma multiforme than in controls. This increase 
      in the frequency of Tr cells that display suppressive activity might play a role 
      in modulation of the immune response against glioma. In light of these findings, 
      Tr cells may represent a potential target for immunotherapy of malignant brain 
      tumors.
FAU - El Andaloussi, Abdeljabar
AU  - El Andaloussi A
AD  - Section of Neurosurgery, The University of Chicago, Chicago, IL 60637, USA.
FAU - Lesniak, Maciej S
AU  - Lesniak MS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060524
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (CD4 Antigens)
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Interleukin-2 Receptor alpha Subunit)
SB  - IM
MH  - Adult
MH  - CD4 Antigens/blood
MH  - CD4-Positive T-Lymphocytes/immunology/metabolism
MH  - Female
MH  - Forkhead Transcription Factors/*blood
MH  - Glioblastoma/*blood
MH  - Humans
MH  - Interleukin-2 Receptor alpha Subunit/*blood
MH  - Lymphocytes, Tumor-Infiltrating/immunology/*metabolism
MH  - Male
MH  - Middle Aged
MH  - T-Lymphocytes, Regulatory/immunology/*metabolism
PMC - PMC1871953
EDAT- 2006/05/26 09:00
MHDA- 2006/12/21 09:00
PMCR- 2007/07/01
CRDT- 2006/05/26 09:00
PHST- 2006/05/26 09:00 [pubmed]
PHST- 2006/12/21 09:00 [medline]
PHST- 2006/05/26 09:00 [entrez]
PHST- 2007/07/01 00:00 [pmc-release]
AID - 15228517-2006-006 [pii]
AID - neu0803p234 [pii]
AID - 10.1215/15228517-2006-006 [doi]
PST - ppublish
SO  - Neuro Oncol. 2006 Jul;8(3):234-43. doi: 10.1215/15228517-2006-006. Epub 2006 May 
      24.